𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile

✍ Scribed by Maritza Ríos; Elena Delgado; Lucía Pérez-Álvarez; Jorge Fernández; Paula Gálvez; Elena Vázquez de Parga; Verónica Yung; Michael M. Thomson; Rafael Nájera

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
310 KB
Volume
79
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This study reports the analysis of human immunodeficiency virus type 1 (HIV‐1) protease (PR) and reverse transcriptase (RT) coding sequences from 136 HIV‐1‐infected subjects from Chile, 66 (49%) of them under antiretroviral (ARV) treatment. The prevalence of mutations conferring high or intermediate resistance levels to ARVs was 77% among treated patients and 2.5% among drug‐naïve subjects. The distribution of resistance prevalence in treated patients by drug class was 61% to nucleoside RT inhibitors, 84% to nonnucleoside RT inhibitors, and 46% to PR inhibitors. Phylogenetic analysis revealed that 115 (85%) subjects were infected with subtype B viruses, 1 with a subtype F1 virus, and 20 (15%) carried BF intersubtype recombinants. Most BF recombinants grouped into two clusters, one related to CRF12_BF, while the other could represent a new circulating recombinant form (CRF). In conclusion, this is the first report analysing the prevalence of ARV resistance which includes patients under HAART from Chile. Additionally, phylogenetic analysis of the PR–RT coding sequences reveals the presence of BF intersubtype recombinants. J. Med. Virol. 79: 647–656, 2007. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Antiretroviral drug resistance among HIV
Antiretroviral drug resistance among HIV-1 infected children failing treatment
✍ Jane Mullen; Susan Leech; Siobhan O'Shea; Ian L. Chrystie; Gillian du Mont; Coli 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract High levels of HIV‐1 replication occur following perinatal infection and antiretroviral drugs may not fully suppress viral load during the early years of childhood. Adherence to treatment may also be difficult among children. These two factors will contribute to development of drug resi

HIV-1 primary and secondary antiretrovir
HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil
✍ Ludimila Paula Vaz Cardoso; Gisner Alves Souza Pereira; Ângela Alves Viegas; Lui 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract Antiretroviral (ARV) resistance mutations in HIV‐1 may reduce the efficacy of prophylactic therapy to mother‐to‐child transmission and impact future treatment options. ARV resistance mutations and HIV‐1 phylogenetic diversity in protease (PR) and reverse transcriptase (RT) genes were as

Genotypic tropism of antiretroviral-trea
Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1
✍ Milosz Parczewski; Magdalena Leszczyszyn-Pynka; Anna Urbanska; Dorota Bander; An 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB

## Abstract CCR5 inhibitors remain an attractive antiretroviral treatment option for HIV‐infected patients; however, tropism testing should be utilized prior their introduction. This study analyzed genotypic HIV‐1 tropisms in patients with evidence of genotypic drug resistance to antiretroviral the

Prevalence and risk factors associated w
Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children
✍ Constance Delaugerre; Josiane Warszawski; Marie-Laure Chaix; Florence Veber; Eug 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract In the USA and West Europe, nearly 80% of HIV‐1‐infected adults, experiencing virologic failure, harbored virus strain resistant to at least one antiretroviral drug. Limited data are available on antiretroviral drug resistance in pediatric HIV infection. The aims of this study were to a

Overcoming resistance to existing therap
Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugs
✍ Carlo-Federico Perno; Graeme Moyle; Chris Tsoukas; Winai Ratanasuwan; Jose Gatel 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Abstract Resistance to available antiretroviral (ARV) agents is of increasing concern, and development of novel agents that address this problem has been identified as a major public health priority. As ARV resistance becomes more prevalent with extended use of existing agents, individuals with